A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug combination as a possible treatment for anaplastic
lymphoma kinase-positive (ALK+) non-small cell lung cancer.
The drugs involved in this study are:
- Alectinib
- Cobimetinib